4.5 Review

Economic Impact of Childhood and Adult Aitention-Deficit/Hyperactivity Disorder in the United States

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jaac.2012.07.008

Keywords

ADHD; cost of illness; societal costs; children; adults

Funding

  1. Shire Development LLC
  2. Pfizer
  3. Shire
  4. Agency for Health Research and Quality
  5. National Library of Medicine
  6. National Science Foundation
  7. Amgen
  8. Bayer Healthcare
  9. Biogen
  10. Bioscience
  11. Boston Scientific
  12. Covidien
  13. Doichi-Sankyo
  14. EMD Serono
  15. Endo
  16. Medtronic
  17. Merck
  18. Millennium
  19. Novartis
  20. Teva North America

Ask authors/readers for more resources

Objective: Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent mental disorders in children in the United States and often persists into adulthood with associated symptomatology and impairments. This article comprehensively reviews studies reporting ADHD-related incremental (excess) costs for children/adolescents and adults and presents estimates of annual national incremental costs of ADHD. Method: A systematic search for primary United States-based studies published from January 1, 1990 through June 30, 2011 on costs of children/adolescents and adults with ADHD and their family members was conducted. Only studies in which mean annual incremental costs per individual with ADHD above rion-ADHD controls were reported or could be derived were included. Per-person incremental costs were adjusted to 2010 U.S. dollars and converted to annual national incremental costs of ADHD based on 2010 U.S. Census population estimates, ADHD prevalence rates, number of household members, and employment rates by age group. Results: Nineteen studies met the inclusion criteria. Overall national annual incremental costs of ADHD ranged from $143 to $266 billion (B). Most of these costs were incurred by adults ($105B-$194B) compared with children/adolescents ($38B-$72B). For adults, the largest cost category was productivity and income losses ($87B-$138B). For children, the largest cost categories were health care ($21B-$44B) and education ($15B-$25B). Spillover costs borne by the family members of individuals with ADHD were also substantial ($33B-$43B). Conclusion: Despite a wide range in the magnitude of the cost estimates, this study indicates that ADHD has a substantial economic impact in the United States. Implications of these findings and future directions for research are discussed. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(10):990-1002.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available